Online inquiry

IVTScrip™ mRNA-Anti-S, AZD8895(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3455MR)

This product GTTS-WQ3455MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, AZD8895(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ3455MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3661MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1213790
GTTS-WQ8915MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ4359MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-188667
GTTS-WQ11301MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI-522
GTTS-WQ12909MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ7986MR IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GX-H9
GTTS-WQ4158MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BI-754091
GTTS-WQ13932MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-2810
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW